📰 Data Presented News
Page 2 - Data Presented News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Data Presented. Real-time updates on events, politics, business and more.
August 7, 2023
/PRNewswire/ -- Leal Health ("Leal" or "the Company"), formerly known as Trialjectory, an AI-powered treatment decision support platform that democratizes...
June 22, 2023
Vaccitech, a biopharmaceutical company, has created a vaccine named VTP-300. They are currently showcasing positive initial results through a poster presentation at the ongoing European Association for the Study of the Liver (EASL) Congress 2023.
April 17, 2023
-- CORAL-CEPI: Primary series samRNA vaccination elicits strong neutralizing antibody responses that persist for at least 6 months, including variant cross-reactive nAb, in previously unvaccinated ... | April 17, 2023
January 4, 2023
/PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the...
December 12, 2022
– Data showcase the potential of glofitamab and mosunetuzumab to address diverse patient needs – – Data presented at ASH 2022 and simultaneously published in the New England Journal of Medicine showed that glofitamab, given as a fixed course, induced early and durable responses in people with heavily pretreated large B-cell lymphoma – – 27-month follow-up data showed mosunetuzumab continued to induce high and durable responses in people with relapsed or refractory f...
December 5, 2022
—Data Presented at CTAD Conference Shows that AlzoSure® Predict Can Accurately Identify Stage of Cognitive Decline and Predict Whether Individuals Will...
December 5, 2022
NE3107-treated patients experienced greater motor control in Parkinson’s trial Patients treated with the combination of NE3107 and levodopa saw...
October 2, 2022
Treatment with Aficamten Associated with Significant Improvements in Symptoms and Quality of Life Additional Data Presented in Poster Session Shows...
September 11, 2022
88% overall response rate (15 out of 17) from interim data of pan-FGFR treatment (FGFRi)-naïve FGFR2-fusion cholangiocarcinoma (CCA) patients treated
September 6, 2022
Improving cancer outcomes via improved prevention and early detection and treatment, and better educating oncologists to implement the latest discoveries, will be the focus of the ESMO Congress 2022.